Literature DB >> 339970

A phase II clinical trial of peptichemio. Clinical screening cooperative group of European Organisation on Research on Treatment of Cancer (E.O.R.T.C).

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 339970

Source DB:  PubMed          Journal:  Biomedicine        ISSN： 0300-0893


× No keyword cloud information.
  4 in total

Review 1.  New cancer chemotherapy drugs in Europe.

Authors:  G Mathé; L M van Putten
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

2.  Phase-II trial with vindesine for regression induction in patients with leukemias and hematosarcomas.

Authors:  M Bayssas; J Gouveia; P Ribaud; M Musset; F de Vassal; J L Pico; L de Luca; J L Misset; D Machover; D Belpomme; L Schwarzenberg; C Jasmin; M Hayat; G Mathé
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

3.  Increased cancericidal activity of PTT.119, a new synthetic bis-(2-chloroethyl)amino-L-phenylalanine derivative with carrier amino acids. I. In vitro cytotoxicity.

Authors:  M J Yagi; J G Bekesi; M D Daniel; J F Holland; A De Barbieri
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

4.  Peptichemio induction therapy in myelomatosis.

Authors:  G Merlini; P G Gobbi; A Riccardi; G Riva; C Sardi; S Perugini
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.